We speculate that low NRDP1 expression in HER2-amplified breast cancers could be mechanistically explained by the previous study of Yen et al. [75], in which NRDP1 loss was shown to enhance HER2/HER3-dependent breast tumour cell growth and tumour progression. Here, ERBB3 is linked to neoplasm.